$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000109355715000128 Filed on April 29, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$72.80M	$47.10M
YoY Change	54.56%	59.12%
Cost Of Revenue	$26.30M	$17.30M
YoY Change	52.02%	32.06%
Gross Profit	$46.50M	$29.80M
YoY Change	56.04%	80.61%
Gross Profit Margin	63.87%	63.27%
Selling, General & Admin	$39.40M	$27.60M
YoY Change	42.75%	52.49%
% of Gross Profit	84.73%	92.62%
Research & Development	$19.80M	$14.50M
YoY Change	36.55%	55.91%
% of Gross Profit	42.58%	48.66%
Depreciation & Amortization	$2.400M	$1.900M
YoY Change	26.32%	5.56%
% of Gross Profit	5.16%	6.38%
Operating Expenses	$59.20M	$42.10M
YoY Change	40.62%	53.65%
Operating Profit	-$12.70M	-$12.30M
YoY Change	3.25%	12.84%
Interest Expense	$200.0K	$200.0K
YoY Change	0.0%	0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.90M	-$12.50M
YoY Change	3.2%	12.61%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$12.90M	-$12.50M
YoY Change	3.2%	12.61%
Net Earnings / Revenue	-17.72%	-26.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$165.8K	-$170.5K
COMMON SHARES
Basic Shares Outstanding	77.80M shares	73.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$83.80M	$57.40M
YoY Change	45.99%	26.71%
Cash & Equivalents	$54.20M	$45.70M
Short-Term Investments	$29.60M	$11.70M
Other Short-Term Assets	$3.800M	$3.500M
YoY Change	8.57%	59.09%
Inventory	$18.40M	$8.900M
Prepaid Expenses
Receivables	$40.20M	$23.80M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$146.2M	$93.60M
YoY Change	56.2%	31.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$35.70M	$22.90M
YoY Change	55.9%	25.14%
Goodwill	$3.200M	$3.200M
YoY Change	0.0%	0.0%
Intangibles	$2.600M	$3.400M
YoY Change	-23.53%	-15.0%
Long-Term Investments
YoY Change
Other Assets	$600.0K	$800.0K
YoY Change	-25.0%	-20.0%
Total Long-Term Assets	$43.10M	$31.30M
YoY Change	37.7%	13.82%
TOTAL ASSETS
Total Short-Term Assets	$146.2M	$93.60M
Total Long-Term Assets	$43.10M	$31.30M
Total Assets	$189.3M	$124.9M
YoY Change	51.56%	26.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.90M	$4.800M
YoY Change	127.08%	118.18%
Accrued Expenses	$22.40M	$22.10M
YoY Change	1.36%	76.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.400M	$2.200M
YoY Change	9.09%	214.29%
Total Short-Term Liabilities	$37.00M	$29.70M
YoY Change	24.58%	83.33%
LONG-TERM LIABILITIES
Long-Term Debt	$1.700M	$4.100M
YoY Change	-58.54%	-34.92%
Other Long-Term Liabilities	$2.000M	$1.100M
YoY Change	81.82%	-59.26%
Total Long-Term Liabilities	$2.000M	$1.100M
YoY Change	81.82%	-59.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.00M	$29.70M
Total Long-Term Liabilities	$2.000M	$1.100M
Total Liabilities	$40.70M	$34.90M
YoY Change	16.62%	38.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$510.7M	-$487.9M
YoY Change	4.67%	6.83%
Common Stock	$659.5M	$577.9M
YoY Change	14.12%	8.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$148.6M	$90.00M
YoY Change
Total Liabilities & Shareholders Equity	$189.3M	$124.9M
YoY Change	51.56%	26.42%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$12.90M	-$12.50M
YoY Change	3.2%	12.61%
Depreciation, Depletion And Amortization	$2.400M	$1.900M
YoY Change	26.32%	5.56%
Cash From Operating Activities	$3.400M	-$2.400M
YoY Change	-241.67%	-46.67%
INVESTING ACTIVITIES
Capital Expenditures	$8.000M	$3.900M
YoY Change	105.13%	178.57%
Acquisitions
YoY Change
Other Investing Activities	-$17.90M	-$400.0K
YoY Change	4375.0%	-102.86%
Cash From Investing Activities	-$25.90M	-$4.300M
YoY Change	502.33%	-134.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.500M	$9.700M
YoY Change	-43.3%	259.26%
Debt Paid & Issued, Net	$600.0K	$500.0K
YoY Change	20.0%
Cash From Financing Activities	$4.900M	$9.200M
YoY Change	-46.74%	240.74%
NET CHANGE
Cash From Operating Activities	$3.400M	-$2.400M
Cash From Investing Activities	-$25.90M	-$4.300M
Cash From Financing Activities	$4.900M	$9.200M
Net Change In Cash	-$17.60M	$2.500M
YoY Change	-804.0%	-76.85%
FREE CASH FLOW
Cash From Operating Activities	$3.400M	-$2.400M
Capital Expenditures	$8.000M	$3.900M
Free Cash Flow	-$4.600M	-$6.300M
YoY Change	-26.98%	6.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	79297379	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
CY2015Q1	dei	Trading Symbol TradingSymbol	DXCM
CY2014Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	42400000	USD
CY2015Q1	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	40200000	USD
CY2014Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1600000	USD
CY2015Q1	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1800000	USD
CY2014Q4	dxcm	Clinical Trials ClinicalTrials	400000	USD
CY2015Q1	dxcm	Clinical Trials ClinicalTrials	100000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2014Q1	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	400000	USD
CY2015Q1	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	0	USD
CY2014Q1	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	400000	USD
CY2015Q1	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	0	USD
CY2014Q1	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	1200000	USD
CY2015Q1	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	0	USD
CY2015Q1	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.04
CY2015Q1	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2012Q4	dxcm	Prime Rate Plus PrimeRatePlus	0.005
CY2015Q1	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2013	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	500000	USD
CY2014	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	2500000	USD
CY2015Q1	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	1000000	USD
CY2013Q3	dxcm	Researchand Development Arrangement Valueof Grant ResearchandDevelopmentArrangementValueofGrant	4000000	USD
CY2015Q1	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
CY2015Q1	dxcm	Working Capital WorkingCapital	109200000	USD
CY2014Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	20400000	USD
CY2015Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	21200000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9900000	USD
CY2015Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10900000	USD
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2015Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-300000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	638000000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	659500000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9500000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7100000	shares
CY2014Q4	us-gaap	Assets Assets	184600000	USD
CY2015Q1	us-gaap	Assets Assets	189300000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	145900000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	146200000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11800000	USD
CY2015Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	29600000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11800000	USD
CY2015Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29600000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43200000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45700000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71800000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54200000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2500000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17600000	USD
CY2015Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	83800000	USD
CY2014Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	54300000	USD
CY2015Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	31500000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77600000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79500000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77300000	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79200000	shares
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2015Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12500000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13100000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	16900000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	26300000	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	17300000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	26300000	USD
CY2012Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-11-01
CY2015Q1	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	15000000	USD
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2012	us-gaap	Debt Issuance Costs DebtIssuanceCosts	1100000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	700000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1300000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1900000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17200000	USD
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12100000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	189000000	USD
CY2014Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2015Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-200000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2015Q1	us-gaap	Goodwill Goodwill	3200000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	29800000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	46500000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-100000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1600000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2200000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2200000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-100000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	600000	USD
CY2014Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4000000	USD
CY2015Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5100000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-200000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2400000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-100000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	500000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-200000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2700000	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2600000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	200000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	200000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7400000	USD
CY2015Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10800000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	16000000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	18400000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7600000	USD
CY2015Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6300000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1000000	USD
CY2015Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1300000	USD
CY2015Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P3Y
CY2014Q4	us-gaap	Liabilities Liabilities	44400000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	40700000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184600000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189300000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40600000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	37000000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2015Q1	us-gaap	Long Term Debt LongTermDebt	4100000	USD
CY2015Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1800000	USD
CY2015Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2300000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9200000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4900000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4300000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25900000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2400000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3400000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-12500000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-12900000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	42100000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	59200000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12300000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12700000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	32600000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2700000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5200000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5000000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4000000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3900000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11800000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8500000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8400000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	600000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	600000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-200000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1500000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2000000	USD
CY2014Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	100000	USD
CY2015Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3000000	USD
CY2015Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	22600000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3900000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3900000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3800000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9700000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5500000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2600000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	4700000	USD
CY2014Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1100000	USD
CY2015Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1400000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31200000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35700000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497800000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-510700000	USD
CY2014Q1	us-gaap	Revenues Revenues	47100000	USD
CY2015Q1	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	20600000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	500000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	600000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14500000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19800000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2015Q1	us-gaap	Revenues Revenues	72800000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	46700000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	72800000	USD
CY2014Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2300000	USD
CY2015Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	2400000	USD
CY2014Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2300000	USD
CY2015Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1700000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27600000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39400000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8700000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	15900000	USD
CY2013Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	900000	USD
CY2014Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	800000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1300000	USD
CY2015Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1100000	USD
CY2014Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1000000	USD
CY2015Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1200000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140200000	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	148600000	USD
CY2015Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	200000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73300000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77800000	shares
CY2015Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of</font><font style="font-family:inherit;font-size:10pt;"> continuous glucose monitoring (“CGM”)</font><font style="font-family:inherit;font-size:10pt;"> systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </font><font style="font-family:inherit;font-size:10pt;">U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;"> requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical trial expenses, allowance for bad debt, and share-based compensation expense. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-15-000128-index-headers.html	Edgar Link	pending
0001093557-15-000128-index.html	Edgar Link	pending
0001093557-15-000128.txt	Edgar Link	pending
0001093557-15-000128-xbrl.zip	Edgar Link	pending
dxcm-03312015x10q.htm	Edgar Link	pending
dxcm-20150331.xml	Edgar Link	completed
dxcm-20150331.xsd	Edgar Link	pending
dxcm-20150331_cal.xml	Edgar Link	unprocessable
dxcm-20150331_def.xml	Edgar Link	unprocessable
dxcm-20150331_lab.xml	Edgar Link	unprocessable
dxcm-20150331_pre.xml	Edgar Link	unprocessable
dxcm03312015ex3101.htm	Edgar Link	pending
dxcm03312015ex3102.htm	Edgar Link	pending
dxcm03312015ex3201.htm	Edgar Link	pending
dxcm03312015ex3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2015 Q1 Form 10-Q Financial Statement

#000109355715000128 Filed on April 29, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2015 Q1 Form 10-Q Financial Statement

#000109355715000128 Filed on April 29, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm